Six-month treatment with atypical antipsychotic drugs decreased frontal-lobe levels of glutamate plus glutamine in early-stage first-episode schizophrenia

Naoki Goto1
Reiji Yoshimura1
Shingo Kakeda2
Joji Nishimura2
Junji Moriya2
Kenji Hayashi1
Asuka Katsuki1
Hikaru Hori1
Wakako Umene-Nakano1
Atsuko Ikenouchi-Sugita1
Yukunori Korogi2
Jun Nakamura1

1Department of Psychiatry, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan; 2Department of Radiology, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan

Objective: To study the effects of treatment with atypical antipsychotic drugs on brain levels of glutamate plus glutamine in early-stage first-episode schizophrenia.

Participants: Sixteen patients (eight males, eight females; aged 30 ± 11 years) completed the study.

Methods: We used administered 6 months of atypical antipsychotic drugs and used proton magnetic resonance spectroscopy to evaluate the results.

Results: We found that the administration of atypical antipsychotic drugs for 6 months decreased the glutamate plus glutamine/creatine ratio in the frontal lobe. These results suggest that the administration of atypical antipsychotic drugs for at least 6 months decreased glutamatergic neurotransmissions in the frontal lobe in early-stage first-episode schizophrenia, but there was no difference in frontal-lobe levels between patients and control subjects before administration.

Conclusion: Taking these findings into account, the glutamatergic and GABAergic neurons are implicated in early-stage first-episode schizophrenia, but in complex ways.

Keywords: Proton magnetic resonance spectroscopy, creatine, frontal lobe, parieto-occipital node, left basal ganglia

Introduction
Glutamate’s role in schizophrenia has been investigated in recent years. Abnormal glutamatergic neurotransmission has been reported in human postmortem studies. Proton magnetic resonance spectroscopy (MRS) allows us to examine brain glutamate and glutamine in vivo. Tibbo et al1 reported that the glutamate system might play a role in neuroarchitectural abnormalities seen in schizophrenia and that higher-than-normal glutamatergic metabolites at the early stages of schizophrenia might lead to excitotoxicity, which decreases in the chronic state. Olbrich et al2 also demonstrated that glutamate levels were significantly higher in the left dorsolateral prefrontal cortex in patients with first-episode schizophrenia. In contrast, no difference was found in glutamate plus glutamine between schizophrenia patients and controls in other regions.3,4 Taking these findings into account, brain glutamate levels in schizophrenia seem inconsistent and controversial. The aim of the present study was to investigate the brain levels of glutamate plus glutamine in early-stage first-episode schizophrenia patients. Another aim was to examine the influence of atypical antipsychotic treatment on brain levels of glutamate plus glutamine in the patients. Therefore, we investigated the effects of treatment with atypical antipsychotic drugs for 6 months.
on brain levels of glutamate plus glutamine in the frontal lobe, left basal ganglia, and the parieto-occipital lobe in early-stage first-episode schizophrenia patients treated with atypical antipsychotics.

Methods

Subjects
A total of 23 patients who fulfilled DSM-IV-TR criteria A, B, D, E, and F, but who were within 6 months of disease onset, were recruited for the study, and all underwent MRS evaluation. After 6 months of follow-up, a diagnosis of schizophrenia was established in 20 of 23 patients. Two patients were excluded from the study, one because of the difficulty of performing MRS given his mental condition, and the other because the image quality was impaired by severe artifacts from dental materials. Thus, 18 patients (nine males, nine females; aged 31 ± 12 years) were finally enrolled in the study. All patients were screened using the Structured Clinical Interview for DSM-IV disorders, and exclusion criteria for all groups included current or past serious medical or neurological illness or dependence on alcohol, or illicit substances. The patients’ psychopathology was assessed with the Positive and Negative Syndrome Scale (PANSS). Sixteen (eight males, eight females; 30 ± 11 years) of 18 patients were followed for 6 months. Eighteen healthy volunteers (nine males, nine females; age range 29 ± 11 years) with no current or past psychiatric history were also studied by MRS as sex- and age-matched controls. This study was approved by the Ethics Committee of the University of Occupational and Environmental Health. All participants gave written informed consent to participate in the study.

MRS methodology
All subjects were examined between 4pm and 6pm, by 1H-MRS using a 3T MR system (Signa EXCITE 3T; GE Medical Systems, Waukesha, WI) with a standard quadrature head coil (GE Medical Systems). The regions of interest (ROIs) for 1H-MRS were set for the frontal lobe, the left basal ganglia, and the parieto-occipital lobe. All of these ROIs were placed so as to avoid the lateral ventricle and skull.

We previously obtained brain gamma-aminobutyric acid (GABA) measurements in schizophrenic patients using a MEGA-PRESS sequence 9, and have reported that the reductions in the GABA concentrations were significantly greater in patients at the early stage of schizophrenia than in controls. By using a MEGA-PRESS sequence, the spectroscopic measurements of glutamate and glutamine in the same voxel could be obtained. Thus, in the present study, the glutamate and glutamine levels were acquired with the MEGA-PRESS sequence using the following parameters: repetition time (TR) 3 seconds, echo time (TE) 68 milliseconds, and 128 averages. The total acquisition time for each PRESS spectrum was approximately 6 minutes. All spectra were analyzed by an LC model 12 using phantom-generated basis functions for the MEGA-edited spectra. The line width, signal-to-noise ratio, and baseline of each spectrum were checked to ensure the robustness of the data. Eddy-current correction was applied using an unsuppressed water spectrum at the appropriate echo time. The edited spectra were analyzed using LCM-basis functions that were generated from phantom measurements using the MEGA-PRESS sequence with the appropriate acquisition parameters.

Statistical analysis
The unpaired t-test was used to compare differences in the glutamate plus glutamine/creatinine (Cr) ratios between the schizophrenia group and the control group. Using nonparametric Wilcoxon and Mann–Whitney tests we analyzed differences in glutamate plus glutamine before and after 6 months’ treatment with atypical antipsychotic drugs. The level of significance was set at P < 0.05.

Results
There was no significant difference in age or gender between the healthy controls and the patient groups. The scores of positive (PANSS-P), negative (PANSS-N), general psychopathology (PANSS-G), and total (PANSS-T) in the early schizophrenia patients were 15.9 ± 4.2, 17.2 ± 5.3, 34.2 ± 10.1, and 68.1 ± 17.0 (mean ± standard deviation), respectively. The ratios of glutamate plus glutamine/Cr in the left basal ganglia were significantly higher in the patients than in the controls (0.72 ± 0.16 vs 0.60 ± 0.18, z = −1.930, P = 0.0496), but no differences were found in the frontal lobe (0.79 ± 0.28 vs 0.67 ± 0.40, z = −1.226, P = 0.2057) or parieto-occipital lobe (0.71 ± 0.15 vs 0.74 ± 0.13, z = −0.142, P = 0.8868) (Figure 1). No associations were found between the glutamate plus glutamine/Cr ratios and positive, negative, and general psychopathology scores in PANSS. The administered atypical antipsychotic drugs and mean dosage were as follows: risperidone (n = 5), 2.9 mg; olanzapine (n = 5), 10.1 mg; aripiprazole (n = 4), 16.2 mg; and quetiapine (n = 2), 250 mg. The mean reduction of positive, negative, general psychopathology, and total scores of
PANSS after 6 months’ treatment with atypical antipsychotic drugs were 33.3, 26.3, 31.4, and 25.3%, respectively. Six months’ administration of atypical antipsychotic drugs reduced the glutamate plus glutamine/Cr ratio in the frontal lobe (before, 0.78 ± 0.28; after 6 months, 0.57 ± 0.18: \( z = -2.792, P = 0.052 \)), whereas, those in the left basal ganglia (before, 0.76 ± 0.15; after 6 months, 0.65 ± 0.19: \( z = -1.448, P = 0.1477 \)), and parieto-occipital lobe (before, 0.73 ± 0.19; after 6 months, 0.69 ± 0.11: \( z = -1.008, P = 0.3132 \)) were not changed by the medication (Figure 2). No correlation was observed between the changes in any scores of PANSS and the changes in the glutamate plus glutamine/Cr ratios.

**Discussion**

We found that the glutamate plus glutamine/Cr ratio in the left basal ganglia was significantly higher in early-stage first-episode schizophrenia patients than in control subjects. No differences were observed in the frontal lobe and parieto-occipital lobe between the two groups. Findings regarding glutamatergic metabolites in schizophrenia have been controversial. Stanley et al. and Ohrmann et al. reported no change in prefrontal glutamate levels in treatment-naïve first-episode schizophrenia patients. Theberge et al. found increased glutamate in the left anterior cingulate cortex and thalamus of treatment-naïve first-episode schizophrenia patients. The results in the present study were basically in accordance with the results of Stanley et al., Ohrmann et al., Bustillo et al., and Reid et al. Recently, great attention has been paid to the basal ganglia, which is an important area of interaction between GABAergic and glutamatergic neurons. De la Fuente-Sandoval et al. first reported that the glutamate/Cr ratio in the dorsal caudate nucleus was higher in drug-naïve schizophrenia patients than in control subjects. The present study’s findings of higher glutamate plus glutamine/Cr ratios in the left basal ganglia did not contradict those of De la Fuente-Sandoval et al. To the best of our knowledge, this is the first report demonstrating that treatment with atypical antipsychotic drugs for at least 6 months decreased the glutamate plus glutamine/Cr ratio in the frontal cortex in early-stage first-episode schizophrenia. However, no correlation was observed between the changes in any scores in PANSS and the changes in glutamate plus glutamine/Cr. Theberge et al. reported that brain glutamate and glutamine levels were significantly decreased in the anterior cingulate cortex, which belongs to the frontal lobe, in patients with chronic medicated schizophrenia. The authors speculated that the findings might indicate a decrease in the number of glutamatergic synapses in this region. On the other hand, we reported that the brain glutamate plus glutamine/Cr ratio was significantly increased, whereas GABA/Cr was significantly reduced in the left basal ganglia in patients with early-stage first-episode schizophrenia, and treatment with atypical antipsychotic drugs did not change brain GABA levels.

It has been reported that glutamatergic and GABAergic neurons might be disturbed in schizophrenia patients, and that these types of neurons interact. Taking these findings into account, glutamatergic neurotransmission might be different in different brain regions and the situation becomes more complicated depending on the stage of schizophrenia. Converging experimental and clinical evidence suggests that dysfunction of proper GABAergic inhibition and...
consequently imbalance between excitation and inhibition in the cerebral cortex underlies at least part of the pathophysiological process of schizophrenia.14 The finding that the brain levels of glutamate plus glutamine at early-stage first-episode schizophrenia were significantly increased in the left basal ganglia, and subsequently decreased in the frontal lobe, but not in the left basal ganglia, suggests that the concentrations and changes in brain GABA and glutamate plus glutamine might vary in different brain regions. In future works, we will measure glutamate and glutamine separately, and in absolute amounts rather than as a Cr ratio, and also use drug-naïve schizophrenia patients as subjects.

**Conclusion**

In conclusion, it is possible that the administration of atypical antipsychotic drugs for at least 6 months decreased glutamatergic neurotransmissions in the frontal lobe in early-stage first-episode schizophrenia patients.

**Acknowledgment**

We thank Mr Toru Sato for his generous help in measuring the MRS.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


